medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 2

<< Back Next >>

Ann Hepatol 2016; 15 (2)

Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B

Zhan-Fei T, Zhong-Lan Y, Yi H, Xue-Mei K, Yu-Ming W

Language: English
References: 35
Page: 174-182
PDF size: 286.64 Kb.


ABSTRACT

Background and aims. CD4+ T cells play an important role in response to hepatitis B virus (HBV) infection. We investigated the change in CD4+ T-cell subpopulations and viral load in patients with chronic HBV infection who were treated with entecavir. Material and methods. Thirty patients with chronic HBV infection were enrolled according to the criteria recommended by the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology. The expressions of signature transcription factors and cytokines of CD4+ T-cell subpopulations were measured in chronic hepatitis B (CHB) patients treated with entecavir treatment. Results. Entecavir treatment significantly attenuated hepatitis B virus DNA load and affected the CD4+ T-cell subsets in CHB patients. A dramatic decrease in the Th17 and Treg cell frequencies and expressions of their related cytokines were found in CHB patients with entecavir treatment. In contrast, entecavir treatment caused a remarkable increase in the Th2 cell frequencies and expressions of their related cytokines. Conclusion. Our results suggested that Th17 and Treg cells were the more sensitive subtypes to entecavir- induced inhibition of HBV replication compared to Th1 and Th2 cells in chronic HBV patients.


REFERENCES

  1. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008; 26: 4557-62.

  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.

  3. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma— epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.

  4. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-39.

  5. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.

  6. Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-8.

  7. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.

  8. Langley DR, Walsh AW, Baldick CJ, Eggerrs BJ, Rose RE, Levine SM, Kapur AJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81: 3992-4001.

  9. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus- HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43: 904-10.

  10. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005; 118: 1413.

  11. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361: 141-8.

  12. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari FV. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010; 107: 798-802.

  13. Yu XP, Guo RY, Su ML, Ming DS, Lin CZ, Deng Y, Lin ZZ, et al. Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. Hepat Mon 2013; 13: e15332.

  14. Zhang L, Wang Q, Zhao P, Hu X, Jiang Y. Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. Clin Exp Pharmacol Physiol 2014; 41: 514-23.

  15. Su ZJ, Yu XP, Guo RY, Ming DS, Huang LY, Su ML, Deng Y, et al. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B. Diagn Microbiol Infect Dis 2013; 76: 437-44.

  16. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi 2006; 14: 643-6.

  17. Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH. Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis. Gastroenterology 1990; 99: 799-804.

  18. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99: 1472-7.

  19. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478-83.

  20. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-80.

  21. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.

  22. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-6.

  23. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300: 337-9.

  24. Li X, Chen Y, Ma Z, Ye B, Wu W, Li L. Effect of regulatory T cells and adherent cells on the expansion of HBcAg-specific CD8+ T cells in patients with chronic hepatitis B virus infection. Cell Immunol 2010; 264: 42-6.

  25. TrehanPati N, Geffers R, Sukriti, Hissar S, Riese P, Toepfer T, Buer J, et al. Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 2009; 49: 781-90.

  26. Atan O, Aksu G, Ozgenc F, Akman SA, Karaca NE, Sertoz R, Yaqci RV, et al. Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha. Turk J Gastroenterol 2010; 21: 401-10.

  27. Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, Zhang X, et al. Effects of telbivudine treatment on the circulating CD4(+) T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm 2012; 789859.

  28. Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm 2010; 143026.

  29. Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, Ebeling SB, et al. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 2002; 32: 1621-30.

  30. Yang YY, Lang ZW, Lan MD, Shi XH, Ma PQ, Shen B, Wang PZ, et al. Expression of intrahepatic CD4+ CD25+ regulatory T cells in patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008; 22: 296-8.

  31. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123: 57-65.

  32. Wu W, Li J, Chen F, Zhu H, Peng G, Chen Z. Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol 2010; 25: 750-7.

  33. Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, Zhao M. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett 2012; 149: 41-9.

  34. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8: 123.

  35. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2010; 5: e13869.




2020     |     www.medigraphic.com